BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11673494)

  • 1. Melphalan-induced expression of IFN-beta in MOPC-315 tumor-bearing mice and its importance for the up-regulation of TNF-alpha expression.
    Jovasevic VM; Mokyr MB
    J Immunol; 2001 Nov; 167(9):4895-901. PubMed ID: 11673494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapeutic outcome.
    Gorelik L; Mokyr MB
    Cancer Immunol Immunother; 1995 Dec; 41(6):363-74. PubMed ID: 8635194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells.
    Donepudi M; Jovasevic VM; Raychaudhuri P; Mokyr MB
    Cancer Immunol Immunother; 2003 Mar; 52(3):162-70. PubMed ID: 12649745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of melphalan-induced B7-1 gene expression in P815 tumor cells.
    Donepudi M; Raychaudhuri P; Bluestone JA; Mokyr MB
    J Immunol; 2001 Jun; 166(11):6491-9. PubMed ID: 11359799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells.
    Sojka DK; Donepudi M; Bluestone JA; Mokyr MB
    J Immunol; 2000 Jun; 164(12):6230-6. PubMed ID: 10843675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.
    Gorelik L; Rubin M; Prokhorova A; Mokyr MB
    J Immunol; 1995 Apr; 154(8):3941-51. PubMed ID: 7706732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor.
    Mokyr MB; Kalinichenko TV; Gorelik L; Bluestone JA
    J Immunol; 1998 Feb; 160(4):1866-74. PubMed ID: 9469448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a beta-adrenergic receptor mechanism and decreased TNF-alpha gene expression.
    Kalinichenko VV; Mokyr MB; Graf LH; Cohen RL; Chambers DA
    J Immunol; 1999 Sep; 163(5):2492-9. PubMed ID: 10452985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.
    Mokyr MB; Rubin M; Newell KA; Prokhorova A; Bluestone JA
    J Immunol; 1993 Nov; 151(9):4838-46. PubMed ID: 8409442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.
    Gorelik L; Prokhorova A; Mokyr MB
    Cancer Immunol Immunother; 1994 Aug; 39(2):117-26. PubMed ID: 8044831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.
    Mokyr MB; Barker E; Weiskirch LM; Takesue BY; Pyle JM
    Cancer Res; 1989 Aug; 49(16):4597-606. PubMed ID: 2568174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.
    Weiskirch LM; Bar-Dagan Y; Mokyr MB
    Cancer Immunol Immunother; 1994 Apr; 38(4):215-24. PubMed ID: 8168116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy.
    Takesue BY; Pyle JM; Mokyr MB
    Cancer Res; 1990 Dec; 50(23):7641-9. PubMed ID: 2123740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers.
    Weiskirch LM; Baumgartel BA; Barker E; Mokyr MB
    Cancer Immunol Immunother; 1991; 32(6):353-63. PubMed ID: 1901031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin 2 requirement for the in vitro generation of antitumor cytotoxicity by thymocytes from melphalan-cured MOPC-315 tumor bearers.
    Mokyr MB; Bartik MM; Ahn MC
    Cancer Res; 1989 Feb; 49(4):870-6. PubMed ID: 2783557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
    Weiskirch LM; Mokyr MB
    Int J Cancer; 1992 Apr; 51(1):84-92. PubMed ID: 1563847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cooperation between staphylococcal enterotoxin B and low dose melphalan in the cure of mice bearing a large MOPC-315 tumor and extensive metastases.
    Rubin M; Bluestone JA; Newell KA; Prokhorova A; Mokyr MB
    J Immunol; 1994 Apr; 152(7):3522-9. PubMed ID: 8144932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
    Barker E; Wise JA; Dray S; Mokyr MB
    Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.
    Bartik MM; Takesue BY; Mokyr MB
    Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma.
    Ben-Efraim S; Shoval S; Ophir R
    Cancer Immunol Immunother; 1986; 22(1):43-8. PubMed ID: 2939947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.